I-Tech AB (ITECH.ST)
SEK 83.0
(7.79%)
SEK 83.0
(7.79%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -83.26 Million SEK | -64.87% |
| 2022 | -50.5 Million SEK | -64.39% |
| 2021 | -30.72 Million SEK | 5.07% |
| 2020 | -32.36 Million SEK | -17.54% |
| 2019 | -27.53 Million SEK | 16.97% |
| 2018 | -33.15 Million SEK | -470.72% |
| 2017 | -5.81 Million SEK | -156.4% |
| 2016 | -2.26 Million SEK | -37.5% |
| 2015 | -1.64 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -94.26 Million SEK | -12.5% |
| 2024 Q1 | -97.73 Million SEK | -17.39% |
| 2024 Q2 | -83.79 Million SEK | 14.27% |
| 2023 Q4 | -83.26 Million SEK | 1.57% |
| 2023 FY | -83.26 Million SEK | -64.87% |
| 2023 Q1 | -63.62 Million SEK | -25.98% |
| 2023 Q2 | -69.77 Million SEK | -9.68% |
| 2023 Q3 | -84.59 Million SEK | -21.23% |
| 2022 Q4 | -50.5 Million SEK | -4.47% |
| 2022 FY | -50.5 Million SEK | -64.39% |
| 2022 Q1 | -35.94 Million SEK | -17.0% |
| 2022 Q2 | -38.89 Million SEK | -8.21% |
| 2022 Q3 | -48.34 Million SEK | -24.29% |
| 2021 Q1 | -36.28 Million SEK | -12.13% |
| 2021 FY | -30.72 Million SEK | 5.07% |
| 2021 Q4 | -30.72 Million SEK | -10.51% |
| 2021 Q3 | -27.79 Million SEK | 5.45% |
| 2021 Q2 | -29.39 Million SEK | 18.99% |
| 2020 Q2 | -31.56 Million SEK | -3.42% |
| 2020 Q3 | -37.37 Million SEK | -18.41% |
| 2020 Q4 | -32.36 Million SEK | 13.42% |
| 2020 Q1 | -30.52 Million SEK | -10.86% |
| 2020 FY | -32.36 Million SEK | -17.54% |
| 2019 FY | -27.53 Million SEK | 16.97% |
| 2019 Q2 | -30.08 Million SEK | 12.9% |
| 2019 Q4 | -27.53 Million SEK | 9.37% |
| 2019 Q3 | -30.37 Million SEK | -0.97% |
| 2019 Q1 | -34.54 Million SEK | -4.18% |
| 2018 Q3 | -35.28 Million SEK | 6.38% |
| 2018 Q4 | -33.15 Million SEK | 6.03% |
| 2018 FY | -33.15 Million SEK | -470.72% |
| 2018 Q2 | -37.69 Million SEK | -251.71% |
| 2018 Q1 | -10.71 Million SEK | -84.46% |
| 2017 Q4 | -5.81 Million SEK | 0.0% |
| 2017 FY | -5.81 Million SEK | -156.4% |
| 2017 Q1 | 17.12 Million SEK | 0.0% |
| 2016 FY | -2.26 Million SEK | -37.5% |
| 2015 FY | -1.64 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -2.16 Million SEK | -3752.938% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 75.043% |
| NextCell Pharma AB | -46.79 Million SEK | -77.946% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -183.368% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 150.135% |
| AcouSort AB (publ) | -23.98 Million SEK | -247.127% |
| OncoZenge AB (publ) | -12.62 Million SEK | -559.397% |
| Xintela AB (publ) | -7.8 Million SEK | -966.231% |
| Ziccum AB (publ) | -2.13 Million SEK | -3796.21% |
| Active Biotech AB (publ) | -33.2 Million SEK | -150.789% |
| Alzinova AB (publ) | -21.22 Million SEK | -292.264% |
| Amniotics AB (publ) | -5.63 Million SEK | -1378.374% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -66.454% |
| BioArctic AB (publ) | -606.58 Million SEK | 86.274% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1641.889% |
| Camurus AB (publ) | -1.16 Billion SEK | 92.855% |
| Cantargia AB (publ) | -139.74 Million SEK | 40.419% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -8920.802% |
| CombiGene AB (publ) | -101.44 Million SEK | 17.92% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -1.433% |
| Genovis AB (publ.) | -43.94 Million SEK | -89.486% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 0.572% |
| Mendus AB (publ) | -96.29 Million SEK | 13.534% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 39.73% |
| Kancera AB (publ) | -45.69 Million SEK | -82.224% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -1.29% |
| LIDDS AB (publ) | -13.51 Million SEK | -516.208% |
| Lipum AB (publ) | -8.46 Million SEK | -883.603% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -160.789% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 256.44% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -336.842% |
| Saniona AB (publ) | 40.44 Million SEK | 305.855% |
| Simris Alg AB (publ) | 85.07 Million SEK | 197.869% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 35.703% |
| Intervacc AB (publ) | -88.16 Million SEK | 5.556% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -66.744% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 505.958% |
| Corline Biomedical AB | -17.01 Million SEK | -389.431% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 0.574% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -111.421% |
| Aptahem AB (publ) | 2.9 Million SEK | 2962.573% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 74.697% |
| Fluicell AB (publ) | -2.76 Million SEK | -2913.464% |
| Biovica International AB (publ) | -58.73 Million SEK | -41.754% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -84.139% |
| Abliva AB (publ) | -57.24 Million SEK | -45.461% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 57.236% |
| 2cureX AB (publ) | -13.4 Million SEK | -521.219% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 161.809% |
| Cyxone AB (publ) | -16.67 Million SEK | -399.472% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -48.985% |
| Biosergen AB | -1.88 Million SEK | -4321.774% |
| Nanologica AB (publ) | -9.38 Million SEK | -786.898% |
| SynAct Pharma AB | -61.75 Million SEK | -34.82% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -288.802% |
| BioInvent International AB (publ) | -236.3 Million SEK | 64.765% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -529.381% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -24.42% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -1507.089% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -300.433% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -2701.548% |